All In Biotech

Drug Trial Radar · NCT06389877

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Jun 19, 2024

Primary completion

May 2028

Study completion May 2030

Sponsor

Lead sponsor
Beam Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Apr 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multicenter, open-label study conducted in 3 parts (Part A, Part B, and Part C) to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease. Parts A and B are designed to evaluate safety and tolerability and identify the optimal biological dose (OBD) in patients with AATD-associated lung disease (Part A) and/or liver disease (Part B), with optional expansion cohorts to further evaluate a potential OBD. Part C is designed to demonstrate the efficacy and safety of BEAM-302 at the OBD in patients with AATD-associated lung disease with or without liver disease in the pivotal cohort.

Conditions

  • Alpha 1-Antitrypsin Deficiency

Interventions

  • BEAM-302Drug

    BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rates of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: 3 years
  2. Absolute blood levels of total AATTime frame: 3 Years
  3. Mean total and functional AAT in bloodTime frame: 1 year

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Study Center

    Birmingham, Alabama · Recruiting

  • Clinical Study Center

    Boston, Massachusetts · Recruiting

  • Clinical Study Center

    Charleston, South Carolina · Recruiting

  • Clinical Study Center

    Adelaide, Australia · Recruiting

  • Clinical Study Center

    Fitzroy, Australia · Recruiting

  • Clinical Study Center

    Dublin, Ireland · Recruiting

  • Clinical Study Center

    Leiden, Netherlands · Recruiting

  • Clinical Study Center

    Auckland, New Zealand · Recruiting

  • Clinical Study Center

    Hamilton, New Zealand · Recruiting

  • Clinical Study Center

    Birmingham, United Kingdom · Recruiting

  • Clinical Study Center

    London, United Kingdom · Recruiting

  • Clinical Study Center

    Southampton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.